Docebo Beats Q1 Expectations; BUY Thesis Bolstered

What happened

Docebo reported Q1 2026 results that exceeded expectations, citing strong momentum into the year. The company continues to benefit from AI-driven upskilling demand and its FedRAMP expansion. However, the release lacks specific metrics (ARR, NRR, cRPO), which are critical to validate growth durability. The positive headline aligns with the existing BUY thesis, which is supported by profitable growth, net cash, and flexible financing. Still, investors should watch for detailed KPI disclosures in the full filing to confirm sustained mid-teens growth and AI module attach rates.

Implication

The Q1 beat reinforces the bullish thesis on Docebo's execution and market positioning. However, the lack of quantified results (ARR, NRR, cRPO) leaves key questions unanswered. Investors should view this as a positive data point that increases confidence, but should not upgrade the thesis until the full financials confirm sustained mid-teens growth and stable or improving NRR. The existing watch items (AI monetization, public-sector wins, competitive pressure) remain relevant. A full analysis of the 10-Q will be necessary to adjust conviction.

Thesis delta

The Q1 super-expectations result leaning positive on the 'ARR/NRR trajectory' and 'AI module attach' watch items, but no numerical disclosures preclude a thesis upgrade. The deep-value BUY stance is reinforced yet remains conditional upon forthcoming detailed KPIs.